ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2011, 'Dose effects of Oxaliplatin on persistent and transient na+ conductances and the development of neurotoxicity', PLoS One, 6, pp. 1 - 7, http://dx.doi.org/10.1371/journal.pone.0018469
,2011, 'Fixed dose rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 16, pp. 519 - 519
,2011, 'Grappling with cultural differences; Communication between oncologists and immigrant cancer patients with and without interpreters', Patient Education and Counseling, 84, pp. 398 - 405
,2011, 'If I Am in the Mood, I Enjoy It: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer', Oncologist, 16, pp. 1333 - 1344
,2011, 'Long-term neuropathy after Oxaliplatin treatment: Challenging the dictum of reversibility', Oncologist, 16, pp. 708 - 716, http://dx.doi.org/10.1634/theoncologist.2010-0248
,2011, 'Management of metastatic renal cell carcinoma in the era of targeted therapies', Internal Medicine Journal, 41, pp. 594 - 605
,2011, 'Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 29, pp. e553 - e554e
,2011, 'Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis', Lancet Oncology, 12, pp. 1240 - 1248, http://dx.doi.org/10.1016/S1470
,2011, 'Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group', Leukemia and Lymphoma, 52, pp. 786 - 795, http://dx.doi.org/10.3109/10428194.2010.547155
,2011, 'Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab', Annals of Oncology, 22, pp. 1834 - 1838
,2011, 'Supporting treatment decision-making in advanced cancer: a randomized trial of a decision aid for patients considering chemotherapy in advanced colorectal cancer', Journal of Clinical Oncology, 29, pp. 2077 - 2084, http://dx.doi.org/10.1200/JCO.2010.32.0754
,2011, 'Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy', Experimental Neurology, 227, pp. 120 - 127, http://dx.doi.org/10.1016/j.expneurol.2010.10.002
,2010, 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study', Journal of Clinical Oncology, 28, pp. 3191 - 3198, http://dx.doi.org/10.1200/JCO.2009.27.7723
,2010, 'A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS).', Journal of Clinical Oncology, 28, pp. 3509 - 3509, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3509
,2010, 'Influence of fatigue after breast cancer adjuvant theraphy on health care utilization and percieved needs', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.9047
,2010, 'Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).', Journal of Clinical Oncology, 28, pp. 3538 - 3538, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3538
,2010, 'Pharmacogenetic factors predicting the need for a higher dose of imatinib.', Journal of Clinical Oncology, 28, pp. 3098 - 3098, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3098
,2010, 'Antitumor effect of somatostatin analogs in neuroendocrine tumors', Journal of Clinical Oncology, 28, http://dx.doi.org/10.1200/JCO.2009.26.0612
,2010, 'A randomized controlled trial of a standardized educational intervention for patients with cancer pain', Journal of Pain and Symptom Management, 40, pp. 49 - 59, http://dx.doi.org/10.1016/j.jpainsymman.2009.12.013
,2010, '5. A novel biomarker of axonal dysfunction in oxaliplatin-induced neurotoxicity', Clinical Neurophysiology, 121, pp. e2 - e2, http://dx.doi.org/10.1016/j.clinph.2009.10.025
,2010, 'A randomized controlled trial of a standardized educational intervention for patients with cancer pain', Journal of Pain and Symptom Management, 49, pp. 49 - 59
,2010, 'Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?', European Journal of Cancer, 46, pp. 1800 - 1807
,2010, 'Adjuvant chemotherapy with flurouracil plus folinic acid vs gemcitabine following pancreatic cancer resection:a randomsied trial JAMA 2010', JAMA - Journal of the American Medical Association, 304, pp. 1073 - 1081
,2010, 'From inside the bubble: Migrants' perceptions of communication with the cancer tea', Supportive Care in Cancer, 19, pp. 281 - 290
,2010, 'Immunohistochemistry for SDHB divides gastrointestinal stromal tumours (GISTs) into two distinct types', American Journal of Surgical Pathology, 34, pp. 636 - 644
,2010, 'Optimising the benefit: a phase II trial of Gemcitabine in fixed dose rate infusion combined with Cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology
,2010, 'Reaching Further with Online Education? The Development of an Effective Online Program in Palliative Oncology', Journal of Cancer Education, 25, pp. 317 - 323
,2010, 'Risk and Response Adapted Therapy for Early Stage Hodgkin Lymphoma: A Prospective Multi-Centre Study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group', Leukemia and Lymphoma, 52, pp. 786 - 795, http://dx.doi.org/10.3109/10428194.2010.547155
,2010, 'Role of pancreatic stellate cells in pancreatic cancer metastasis', American Journal of Pathology, 177, pp. 2585 - 2596, http://linkinghub.elsevier.com/retrieve/pii/S0002-9440(10)60308-2
,2010, 'Tamoxifen use in retroperitoneal fibrosis, case report and review of the literature', Internal Medicine Journal, 40, pp. e5 - e7
,2010, 'Tamoxifen use in retroperitoneal fibrosis.', Intern Med J, 40, pp. e5 - e7, http://dx.doi.org/10.1111/j.1445-5994.2010.02373.x
,2010, 'Treatment of Fluorouracil-Refractory Patients with Liver Metastases from Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy', Journal of Clinical Oncology, 27, pp. 4089 - 4095
,2009, 'Normal Pancreatic Stellate Cells Facilitate Pancreatic Cancer Progression, Exhibit Transendothelial Migration and Accompany Cancer Cells to Distant Metastatic Sites', PANCREAS, 38, pp. 1062 - 1062, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000271225300403&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma', Journal of Clinical Oncology, 27, pp. LBA4505 - LBA4505, http://dx.doi.org/10.1200/jco.2009.27.18s.lba4505
,2009, 'ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma', Journal of Clinical Oncology, 27, pp. LBA4505 - LBA4505, http://dx.doi.org/10.1200/jco.2009.27.18_suppl.lba4505
,2009, 'ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma', Journal of Clinical Oncology, 27, pp. LBA4505 - LBA4505, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.lba4505
,2009, 'GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC).', J Clin Oncol, 27, pp. 4616, http://www.ncbi.nlm.nih.gov/pubmed/27964183
,2009, 'Gene expression profiling of human pancreatic stellate cells and their roles in pancreatic cancer progression.', CANCER RESEARCH, 69, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702804198&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'Heat shock proteins are induced during pancreatic stellate cell activation in pancreatic cancer', CANCER RESEARCH, 69, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209702804197&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2009, 'When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis.', World J Surg Oncol, 7, pp. 8, http://dx.doi.org/10.1186/1477-7819-7-8
,2009, 'WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.', Cochrane database of systematic reviews (Online)
,2009, 'Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 27, pp. 1243 - 1249
,2009, 'Are Australian oncology health professionals burning out? A view from the trenches', European Journal of Cancer, 45, pp. 393 - 399
,2009, 'Are Australian oncology health professionals burning out? A view from the trenches', European Journal of Cancer, 45, pp. 393 - 399
,2009, 'Cancer in the older adult: a tale of two disciplines', Journal of Internal Medicine, 39, pp. 771 - 775
,2009, 'Mapping oncology services in regional and rural Australia', Australian Journal of Rural Health, 17, pp. 321 - 329, http://dx.doi.org/10.1111/j.1440-1584.2009.01106.x
,2009, 'Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer', British Journal of Cancer, 101, pp. 998 - 1004, http://dx.doi.org/10.1038/sj.bjc.6605239
,2009, 'Oxaliplatin-induced Lhermitte’s phenomenon as a manifestation of severe generalized nerve dysfunction', Oncology, 77, pp. 342 - 348
,2009, 'Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy', Brain, 132, pp. 2712 - 2723
,2009, 'Response', Journal of Bioethical Inquiry, 6, pp. 257 - 258
,